department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

EVRYSDI · pharmadog

pharmadog
drugs
EVRYSDI

drug

patient view →

EVRYSDI

Marketedupdated 2mo ago

by Genentech Inc

Approved

community read0 votes

all catalysts(16)

approval · 16

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

view all 16 catalysts →

News(0)

no news has mentioned this drug yet

brand

EVRYSDI

generic

RISDIPLAM

indication

Spinal Muscular Atrophy (SMA)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 3, 2026

88 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

Apr 15, 2041compositionUS 12122789
Apr 15, 2041compositionUS 12122789
Oct 4, 2038method-of-use (U-1943)US 11534444
Oct 4, 2038method-of-use (U-1943)US 11534444
Oct 1, 2038method-of-use (U-1943)US 12350273
Oct 1, 2038method-of-use (U-1943)US 12350273
Nov 8, 2036formulationUS 11938136
Jan 25, 2036method-of-use (U-1943)US 11827646
Jan 25, 2036method-of-use (U-1943)US 11827646
May 11, 2035compositionUS 9969754
May 11, 2035compositionUS 9969754
Feb 8, 2033compositionUS 9586955
Feb 8, 2033compositionUS 9586955

FDA exclusivities (4)

May 27, 2029ODE-400Orphan Drug (7y)2.9y
Aug 7, 2027ODE-334Orphan Drug (7y)1.1y
Oct 3, 2026M-270Method (3y)88d
Oct 3, 2026M-270Method (3y)88d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 52m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 4

drugrisdiplam64 co-mentions · 16 sources
tagApproval64 co-mentions · 16 sources
companyGenentech Inc32 co-mentions · 16 sources
tagSmall Molecule32 co-mentions · 16 sources

Trials studying EVRYSDI

phase4Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)active not recruitingn=403
phase4A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapyrecruitingn=28
phase2A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophyactive not recruitingn=26
phase4A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapyrecruitingn=28
phase2A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophyrecruitingn=10
phase2A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophyrecruitingn=52
phase3A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophyactive not recruitingn=259
—Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restorationcompletedn=18

more trials →